Topic: nasal spray

Impel’s championing of nasal delivery of drugs has been rewarded with new financing that will help it advance three drugs through the clinic.

Milestone Pharmaceuticals has brought in $80 million to fund an at-home, phase 3 clinical trial of its nasal spray for bringing down high heart rates.

Lyra Therapeutics' series B will move its lead program, a rhinosinusitis treatment based on its transmucosal drug delivery platform, into phase 2.

Days after the FDA approved Optinose’s nasal polyp drug, its commercialization will be the focus of a post-IPO spending spree.

The FDA expanded the indication for Medtronic’s NuVent sinus dilation balloon to include patients with scarred, granulated or previously surgically altered tissue.